Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes
Histological and molecular analyses of urothelial carcinoma often reveal intratumoural and
intertumoural heterogeneity at the genomic, transcriptional and cellular levels. Despite the …
intertumoural heterogeneity at the genomic, transcriptional and cellular levels. Despite the …
Defining cisplatin eligibility in patients with muscle-invasive bladder cancer
DM Jiang, S Gupta, A Kitchlu, A Meraz-Munoz… - Nature Reviews …, 2021 - nature.com
The current treatment paradigm for muscle-invasive bladder cancer (MIBC) consists of
cisplatin-based neoadjuvant chemotherapy followed by local definitive therapy, or local …
cisplatin-based neoadjuvant chemotherapy followed by local definitive therapy, or local …
Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder …
A Necchi, D Raggi, A Gallina, JS Ross, E Farè… - European urology, 2020 - Elsevier
Abstract Background The PURE-01 study (NCT02736266) evaluated the use of
pembrolizumab before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC) …
pembrolizumab before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC) …
[HTML][HTML] Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆
Background Initial studies of preoperative checkpoint inhibition before radical cystectomy
(RC) have shown promising pathologic complete responses. We aimed to analyze the …
(RC) have shown promising pathologic complete responses. We aimed to analyze the …
Identification of lineage-specific transcriptional factor–defined molecular subtypes in small cell bladder cancer
Small cell/neuroendocrine bladder cancers (SCBCs) are rare and highly aggressive tumors
that are associated with poor clinical outcomes. We discovered that lineage-specific …
that are associated with poor clinical outcomes. We discovered that lineage-specific …
A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy
Purpose: The currently available evidence regarding the prognostic and clinical significance
of each variant histology subtype of urothelial bladder cancer remains scarce. We assessed …
of each variant histology subtype of urothelial bladder cancer remains scarce. We assessed …
Patients with muscle-invasive bladder cancer with nonluminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy
Purpose: Neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) in patients with
nonmetastatic muscle-invasive bladder cancer (MIBC) confers an absolute survival benefit …
nonmetastatic muscle-invasive bladder cancer (MIBC) confers an absolute survival benefit …
Molecular profile of bladder cancer progression to clinically aggressive subtypes
CC Guo, S Lee, JG Lee, H Chen, M Zaleski… - Nature Reviews …, 2024 - nature.com
Bladder cancer is a histologically and clinically heterogenous disease. Most bladder
cancers are urothelial carcinomas, which frequently develop distinct histological subtypes …
cancers are urothelial carcinomas, which frequently develop distinct histological subtypes …
Genomic tumor correlates of clinical outcomes following organ-sparing chemoradiation therapy for bladder cancer
SC Kamran, Y Zhou, K Otani, M Drumm, Y Otani… - Clinical Cancer …, 2023 - AACR
Purpose: There is an urgent need for biomarkers of radiation response in organ-sparing
therapies. Bladder preservation with trimodality therapy (TMT), consisting of transurethral …
therapies. Bladder preservation with trimodality therapy (TMT), consisting of transurethral …
Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. II. Molecular pathology of …
JI Warrick, MA Knowles, A Yves… - The American Journal …, 2020 - journals.lww.com
Abstract During the 2019 International Society of Urological Pathology Consultation
Conference on Molecular Pathology of Urogenital Cancer, the Working Group on Bladder …
Conference on Molecular Pathology of Urogenital Cancer, the Working Group on Bladder …